These Fluoride Products Are The Latest To Be Targeted By RFK Jr. And The FDA
WASHINGTON (AP) — US health regulators announced an effort Tuesday to phase out ingestible fluoride supplements sometimes used to strengthen children's teeth, opening a new front in Health Secretary Robert F. Kennedy Jr.'s effort against a mainstay of dental care.
The Food and Drug Administration said it will conduct a scientific review of the children's products by late October with the aim of removing them from the market. Formally withdrawing medical products requires a lengthy rulemaking process that can take years. Instead, the FDA will ask manufacturers to voluntarily pull their products, according to an administration official.
Fluoride tablets and lozenges are sometimes recommended for children and teens at increased risk of tooth decay or cavities because of low fluoride in their local drinking water. Companies also sell drops for babies.
Related: Donald Trump Claims The US Will "Take Over" Gaza, And MAGA Supporters Are FINALLY Realizing What They Voted For
FDA Commissioner Marty Makary said the products pose a risk when swallowed because they may interfere with healthy gut bacteria that are critical to digestion, immunity, and other key bodily functions. He also referenced studies showing possible associations between excess fluoride intake and other problems, including decreased IQ. Previous reviews by public health experts and dental professionals have not shown any serious health risks with the products.
Related: A Picture Of Donald Trump's Face Being Two Completely Different Colors Is Going Viral For Obvious Reasons
As state and local governments begin removing fluoride from their water, the need for supplemental fluoride is expected to grow.
Officials in Utah — the first US state to ban fluoride from drinking water — recently made fluoride supplements available without a prescription.
Fluoride strengthens teeth and reduces cavities by replacing minerals lost during normal wear and tear, according to the Centers for Disease Control and Prevention. In 1962, the agency set guidelines for how much should be added to water.
Kennedy, a former environmental lawyer, has called fluoride a 'dangerous neurotoxin' tied to a range of health dangers. Last month, he announced a task force to scrutinize fluoride's use, while at the same time saying he would order the CDC to stop recommending that it be added to tap water.
A report last year by the federal government's National Toxicology Program concluded that drinking water with more than twice the CDC's recommended level was associated with lower IQs in kids. The study was based on research conducted in Canada, China, India, Iran, Pakistan, and Mexico.
'Ending the use of ingestible fluoride is long overdue,' Kennedy said in a statement Tuesday. 'This decision brings us one step closer to delivering on President Trump's promise to Make America Healthy Again.'
An influential government health panel recommends fluoride supplements for children between the ages of six months and 5 years if they live in areas with low fluoridation levels. The US Preventative Services Task Forces judged the recommendation to have 'high certainty,' based on the available evidence.
A 2010 paper from the American Dental Association recommended supplemental fluoride for children up to 16 years old who are at high risk of cavities. The recommendation was based on a review of studies across different age groups. The most common side effect associated with the products is spotting or discoloration of the teeth, caused by extra fluoride.
The ADA did not immediately respond to a request for comment.
The FDA regulates most dental products, including fluoride-containing toothpastes, supplements, mouthwashes, and rinses. But in Tuesday's press release, the FDA said the ingestible products targeted by the agency have 'never been approved.' Its plan wouldn't affect toothpastes, mouthwash, or fluoride treatments used by adults or offered in dentists' offices.
In recent weeks, fluoride-containing products have increasingly been targeted with lawsuits and legal actions.
Texas Attorney General Ken Paxton announced an investigation early this month into the marketing of fluoride toothpastes by Colgate-Palmolive and Proctor and Gamble. A press release from his office described the companies' promotions as 'misleading, deceptive, and dangerous.'
This article originally appeared on HuffPost.
Also in In the News: "We Went From 'Lower The Price Of Eggs' To 'Lower Your Standard Of Living'": 39 Of The Best, Most Brutal, And Very Relatable Political Tweets Of The Month
Also in In the News: "We Don't Import Food": 31 Americans Who Are Just So, So Confused About Tariffs And US Trade
Also in In the News: People Who Voted For Trump Are Getting Very Honest About Donald Trump's Latest Truth Social Post
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
36 minutes ago
- UPI
NIH office to phase out HIV guidelines by next year
The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States is making major changes. File Photo by Annabelle Gordon/UPI | License Photo June 21 (UPI) -- The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States is making major changes. The NIH Office of AIDS Research or OAR told its employees this week it intends to phase out the guidelines by next June, the Washington Post reported, citing an internal staff email. According to the office, OAR "coordinates HIV/AIDS research across the National Institutes of Health and provides the largest public investment in HIV/AIDS research globally." "In the climate of budget decreases and revised priorities, OAR is beginning to explore options to transfer management of the guidelines to another agency within" the letter obtained by The Post reads. The OAR guidelines contain guidelines related to diagnosis and treatments of HIV and AIDS. There are currently more than 1 million people living with HIV in the United States. It was not immediately clear what the other agency referred to in the letter was or how such a move may affect the guideline, the Post reported. The news comes as President Donald Trump and Secretary of State Marco Rubio move to cut over $8 billion from the U.S. Agency for International Development, USAID and merge it into the State Department. State Department officials say the move comes with the expectation that other countries will increase their roles in delivering aid around the world. An April report published in the Lancet medical journal found around half a million children globally could die from AIDS by 2030 if the United States cuts its global relief funding. Earlier this week, the U.S. Food and Drug Administration approved use of the HIV drug lenacapavir, which is produced by California-based biopharma firm Gilead Sciences under the name Yeztugo. "Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic," Gilead Science Chairman and Chief Executive Officer Daniel O'Day said in a statement on the company's website
Yahoo
5 hours ago
- Yahoo
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT). "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs." Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3. Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course. About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@ Russo Partners, LLCNic JohnsonPerspectiveIR@
Yahoo
7 hours ago
- Yahoo
Health care has been a job market bright spot, but Trump's budget bill looms over the industry
Proposed cuts to health insurance programs in the budget bill being pushed through Congress by President Donald Trump could put hundreds of thousands of health care jobs at risk — jeopardizing one of the few notably strong areas of the U.S. job market. Congressional Republicans are advancing a budget plan that would cause nearly 8 million people on Medicaid to lose their health insurance coverage, according to estimates by the Congressional Budget Office, with an additional 2 million people to lose coverage through the Affordable Care Act if Congress remains on track to let health insurance tax subsidies expire at the end of the year. Less funding for Medicaid and fewer people with health insurance would mean a drop-off in doctor's office visits, prescription refills and medical procedures — and, as a result, fewer workers needed to support those types of services. It could lead to the loss of nearly 500,000 health care jobs over the next decade, according to an analysis by George Washington University and the Commonwealth Fund. The expiration of the ACA tax subsidies, which were enacted in 2021, would result in the loss of an additional 140,000 jobs, a separate analysis from George Washington University found. 'Hospitals will close, health centers will close, pharmacies in some parts of the country will close because they will lose revenue,' said Leighton Ku, director for the Center for Health Policy Research at George Washington University, who worked on the analyses. 'There are going to be job losses, and we're talking about middle class jobs being lost.' That would be a blow to one of the strongest, steadiest areas of the job market in recent years. Health care accounted for nearly half of the jobs added in the U.S. in May, according to the Bureau of Labor Statistics. Last year, around half of the 2.2 million jobs added to the economy were in health care-related sectors, according to an analysis by S&P Global. That has helped offset job cuts and stagnant growth in other sectors of the labor market, like retail and manufacturing. 'Right now, a lot of what is driving these positive headline numbers and bolstering the labor market is the health care sector,' said Allison Shrivastava, an economist with job listing site 'It's something that has been a constant. The health care sector has been a pretty big mainstay as the rest of the labor market has cooled.' The health insurance provisions are part of a broader spending bill that has passed the House and is currently making its way through the Senate. The legislation, which Republicans have dubbed the "Big Beautiful Bill Act," would cut around $800 billion from Medicaid, the health insurance program for the poor and disabled, in order to help offset some of the $4 trillion in tax cut extensions in the bill for individuals and corporations. A version of the bill currently in the Senate, which plans to start voting on the legislation next week, would go even further in reducing spending on Medicaid, by including a provision to limit states' use of taxes on hospitals and other health care providers that help states fund their share of the Medicaid program. The cuts would take a particular toll on health care providers in rural areas, where patients are more likely to be insured through Medicaid than those in metro areas. Researchers at Georgetown University found that 40% of children in small and rural towns receive their health insurance from Medicaid. Already, one-third of all rural hospitals in the country are at risk of closing because of financial difficulties, according to a report this month from the Center for Healthcare Quality and Payment Reform. Also at risk are Community Health Centers, which employ more than 300,000 workers and receive a portion of their funding from the federal government. Those centers, which serve at least 32 million mostly lower-income patients a year, get about 40% of their revenue from Medicaid. 'Our health centers operate on razor-thin margins, so any kind of disruption in payments or reimbursements, even for a short time, can have a significant impact,' said Joe Dunn, chief policy officer for the National Association of Community Health Centers. 'About 40% of health centers are in rural America, and oftentimes they are the only primary care in that community. We have health centers in towns of a few hundred people, and there may not be any other kind of health care network there.' Absent any policy changes from Congress, the health care sector had appeared to be on track for continued growth — and largely isolated from wider concerns about tariffs and an economic slowdown. The number of job postings for doctors and surgeons on are about 90% higher than their pre-pandemic levels, listings for home health aides are up 46%, and openings for nurses are up 16%, Shrivastava said. Health care job postings on represent 27% of all active job listings and health care postings are beginning to make up a larger share of new job postings, according to data from ZipRecruiter. A loss of that hiring momentum from funding cuts would leave one less positive driver for the job market. 'Right now, the labor market as a whole is arguably in a stagnant position,' said Shrivastava. 'People are not wanting to leave their jobs, they're nervous about whether or not they'll be able to find another job, and companies aren't really looking to hire. Health care has been the exception to that.' This article was originally published on
